PACB PACIFIC BIOSCIENCES OF CALI...

Nasdaq pacb.com


$ 2.03 $ -0.16 (-7.21 %)    

Tuesday, 04-Nov-2025 19:48:43 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 2
$ 2.15
$ 2.02 x 450
$ 2.10 x 12
-- - --
$ 0.85 - $ 2.72
11,540,886
na
600.74M
$ 2.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-09-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-03-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 02-26-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pacbio-in-partnership-with-berry-genomics-receives-class-iii-medical-device-registration-from-chinas-nmpa-enabling-high-accuracy-long-read-genomic-testing-for-thalassemia-and-other-complex-genetic-disorders

PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced that, through its lon...

 cathie-wood-just-dumped-74-million-worth-of-palantir-and-amd-shares--heres-what-ark-is-buying-instead

Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bought AMD, Pacific Biosciences,...

 pacbio-announced-innovations-to-its-revio-and-vega-platforms-to-lower-sequencing-costs-add-new-multiomic-capabilities-and-expand-support-for-regulated-research-environments

The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to deliver PacBio's most af...

 pacbios-hifi-technology-selected-as-primary-platform-for-korean-pangenome-reference-project

MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-...

 pacbios-revio-systems-chosen-by-national-institute-on-aging-long-life-family-study-to-sequence-genomes-of-7800-participants-in-longevity-study

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that ...

 pacbio-enters-high-throughput-carrier-screening-market-with-expanded-puretarget-kits-for-inherited-conditions

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into...

 epicypher-joins-pacbio-compatible-program-to-enhance-single-molecule-chromatin-sequencing-with-cutana-hia5-enzyme

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher...

 piper-sandler-maintains-neutral-on-pacific-biosciences-raises-price-target-to-15

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price targe...

 pacific-biosciences-q2-adj-eps-013-beats-017-estimate-sales-39766m-beat-36886m-estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $...

 pacbio-and-partners-publish-benchmark-study-in-nature-methods-enhancing-genomic-accuracy-and-reducing-ai-variant-errors-by-34

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of ...

Core News & Articles

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of diseaseBOSTON, Jul...

Core News & Articles

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of diseaseBOSTON, Jul...

Core News & Articles

Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read s...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION